Generate a tailored SOP for Dr. Benjamin Derman. Improve your application with a focused, well-structured draft.
Ben Derman, MD, specializes in hematology oncology. Dr. Derman is an expert in multiple myeloma, plasma cell disorders, monoclonal gammopathy, amyloidosis, and plasmacytoma. He diagnoses and treats cancerous conditions using innovative techniques, such as CAR T-cell therapy and stem cell transplantation, to deliver long-term success for patients. In clinical practice, Dr. Derman remains committed to research. He is currently focused on identifying strategies that lead to a possible cure for multiple myeloma, using sensitive tests to measure small amounts of residual cancer cells in the body called ‘minimal residual disease’ (MRD) to guide decision-making. Dr. Derman is investigating new methods and therapies designed to improve outcomes and quality of life for patients. Additionally, he is interested in evaluating the reasons for racial disparities in multiple myeloma outcomes to better understand the care of patients. His work has been published in peer-reviewed journals including Journal of Immunotherapy of Cancer, Blood, and Advances in Blood Cancer Journal. He has also contributed significantly to research on CAR T-cell therapies and their impacts on neurocognitive toxicity in patients receiving treatment for multiple myeloma.
University of Chicago • Chicago, IL
Assists in the education and training of medical students and residents while engaging in cutting-edge research in hematology and oncology.
Department of Philosophy